Novogen Ltd - Report of Foreign Issuer (6-K)
March 25 2008 - 8:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For the
month of March, 2008
Commission
File Number
________________
Novogen
Limited
(Translation
of registrant’s name into English)
140 Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
o
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
o
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes
o
No
x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf
by the undersigned, thereunto duly
authorized.
Novogen
Limited
(Registrant)
/s/ Ron
Erratt
Ronald
Lea Erratt
Company
Secretary
Date
25 March, 2008
ASX
& MEDIA RELEASE
25
MARCH, 2008
YALE
RESEARCHERS TO PRESENT DATA AT AACR CONFERENCE INDICATING THAT NOVOGEN COMPOUND
NV-128 USES mTOR PATHWAY TO INDUCE CELL DEATH IN CHEMO-RESISTANT OVARIAN CANCER
CELLS
Sydney,
Australia and New Canaan, Connecticut. An abstract for an oral
presentation to be given at the Annual Meeting of the American Association for
Cancer Research, 12-16 April in San Diego, California, is now available
(abstract number 4926). The abstract, describing work undertaken by
Professor Gil Mor and colleagues at the Yale University School of Medicine,
indicates that the compound NV-128, developed by Novogen Limited (ASX:
NRT NASDAQ:NVGN), may be useful for the maintenance of remission in
chemo-resistant ovarian cancer.
NV-128 is
able to induce cell death through the inhibition of the mTOR pathway in cancer
cells. NV-128 inhibition of the mTOR pathway results in
caspase-independent apoptosis and autophagy. Only a few other
compounds are in the mTOR antagonist class, providing an alternative to drug
candidates reliant on caspase dependent cell death as their mechanism of
action.
At the
annual meeting of the Society for Gynecological Oncology in Tampa, earlier this
month, several key speakers addressed the significance of mTOR antagonists in
cancer therapeutics.
mTOR is a
key intracellular kinase, integrating proliferation and survival
pathways. In cancer cells, mTOR signals enhance tumour growth and may
be associated with resistance to conventional therapy. Inhibition of
mTOR may shut down many of these survival pathways, including the proteins
protecting the mitochondria. It is believed that NV-128 affects the
catalytic dynamics of mTOR in order to achieve apoptosis.
NV-128
works differently from therapies that are dependent on caspases to trigger
apoptosis. Through the inhibition of mTOR, NV-128 is capable of
triggering a cascade of events that leads to mitochondrial damage and cell
death. Interestingly, since NV-128-induced cell death is completely
caspase-independent, it could be effective on cancer cells characterised by high
resistance to cell death and representative of late stage chemorefractory
disease..
About
Novogen Limited:
Novogen
Limited (ASX: NRT NASDAQ:
NVGN
) is an
Australian biotechnology company that has patented isoflavone technology for the
treatment and prevention of degenerative diseases and disorders. Over
the past ten years, Novogen has conducted the largest and most comprehensive
isoflavone clinical testing programs in the world. Novogen is
involved in drug discovery and product development for disorders that are
commonly associated with aging and coordinates an international clinical
research and development program with external collaborators, hospitals and
universities. For more information, visit
www.novogen.com
.
Under
US law, a new drug cannot be marketed until it has been investigated in clinical
trials and approved by the FDA as being safe and effective for the intended
use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements, which are
based on management's current expectations and are subject to a number of risks
and uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development and/or
FDA approval, or the failure to obtain such approval, of our product candidates;
uncertainties in clinical trial results; our inability to maintain or enter
into, and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any products;
competitive factors; our inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and intellectual property to
operate our business; our inability to operate our business without infringing
the patents and proprietary rights of others; general economic conditions; the
failure of any products to gain market acceptance; our inability to obtain any
additional required financing; technological changes; government regulation;
changes in industry practice; and one-time events. We do not intend
to update any of these factors or to publicly announce the results of any
revisions to these forward-looking statements.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024